学院（School）:

温州医科大学附属第一医院

The 1st School of Medicine

专业（Discipline）:

肿瘤学Oncology

研究方向（Research Interests）:

1.Tumor Immunology

2. Targeted Therapy

3.Inflammation and tumorigenesis

邮箱（Email）:

Pixu_liu@163.com

个人简历（Biography）

教育背景(Educational Background)

1999/03–2001/12 University of Chicago, Booth School of Business, MBA

1995/08–1996/02 University of Massachusetts Amherst (USA), Ph.D. coursework in Molecular and Cellular Biology

1992/09–1995/07 Peking Union Medical College (Beijing), Institute of Basic Medical Sciences, Department of Cell Biology, M.D, Ph.D.

1989/09–1992/07 Dalian Medical University, Department of Surgery (Clinical Medicine), Master of Medicine

1984/09–1989/07 Dalian Medical University, Department of Clinical Medicine, Bachelor of Medicine

工作经历(Working Experience)

2022/02–Present Wenzhou Medical University, Ist Affiliated Hospital, Professor and Director

2012/12–2022/01 Dalian Medical University, Institute of Cancer Stem Cell

Professor, Director, Center for Translational Medicine in Oncology

2013/11–2019/12 Dalian Institute of Chemical Physics, Chinese Academy of Sciences

Visiting Professor

2006/10–2012/11 Dana-Farber Cancer Institute, Harvard Medical School (USA)

Scientist

2005/07–2006/08 Beth Israel Deaconess Medical Center, Harvard Medical School (USA) Senior Research Associate

2003/02–2005/05 Boston Children’s Hospital, Harvard Medical School (USA)

Research Fellow (Postdoctoral Researcher)

1996/09–1999/03 University of Chicago, Department of Biochemistry and Molecular Biology Postdoctoral Researcher

学术兼职(Part-time Academic Jobs)

Council Member, 1st Committee of China Biomedical Integration Alliance

Committee Member, 1st Gynecological Oncology Committee, Liaoning Society of Cell Biology

Committee Member, Precision Cancer Therapy Committee, Minimally Invasive and Non-Invasive Medical Branch, Chinese Medical Doctor Association

所获荣誉(Awards)

2012 Liaoning Province "Climbing Scholar"

2014 WuXi PharmaTech Human Whole Genome Sequencing Fund Award

2015 Dalian Top Overseas Returnee Talent (5th Cohort)

2015 Dalian Outstanding Contribution to Science and Technology Award

2015 Liaoning Province "Ten-Hundred-Thousand High-Level Talent Introduction Program" (2nd Batch)

2018 Dalian Leading Talent (2nd Cohort)

2020 Liaoning Province Innovation Leading Talent ("Xing Liao Ying Cai Program" Distinguished Professor)

2023 Core Member of Zhejiang Province Technological Innovation Leading Team

发表文章（Representative Publication）

(1) Sang X, Han J, Wang Z, Cai W, Liao X, Kong Z, Yu Z, Cheng H, Liu P, SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways. Oncogene. 2024 Nov; 43 , doi: 10.1038/s41388-024-03173-3.

(2) Shi Q, Xia Y, Wu M, Pan Y, Wu S, Lin J, Kong Y, Yu Z, Zan X, Liu P, Xia J., Mi-BMSCs alleviate inflammation and fibrosis in CC|4-and TAA-induced liver cirrhosis by inhibiting TGF-ß/Smad signaling. Mater Today Bio. 2024 Jan 24:25:100958. doi: 10.1016/i.mtbio.2024.100958.

(3) Gao X, Zhao H, Liu J, Wang M, Dai Z, Hao W, Wang Y, Wang X, Zhang M, Liu P, Cheng H, Liu Z., Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death., Adv Sci (Weinh). 2024 Aug;11(30):e2401396. doi: 10.1002/advs.202401396.

(4) Zhang X, Liao X, Wang M, Liu J, Han J, An D, Zheng T, Wang X, Cheng H, Liu P*. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms. Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16085.

(5) Wang M, Liu J, Liao X, Yi Y, Xue Y, Yang L, Cheng H, Liu P. The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance. Redox Biol. 2023 Nov;67:102931. doi: 10.1016/.redox.2023.102931.

(6) Yang J, Zhang Y, Kong Y, Lin J, Zhu G, Zhang H, Yu Z, Liu P, Xia J., Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma. Braz J Med Biol Res. 2024 Sep 6;57:13661. do: 10.1590/1414-431X2024e13661.

(7) Huang A, Guo F, Yu Z, Liu P, Dong S, Zhang Y, Kong Y, Kong X, Li T, Luo Y, Xia H, Shi K, Xia J., Engineered Apoptosis-Bioinspired Nanoparticles lnitiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites. ACS Appl Mater Interfaces. 2023 Mar 1;15(8):10371-10382. doi: 10.1021/acsami.2c19769.

(8) Liu Z, Sang X, Wang M, Liu Y, Liu J, Wang X, Liu P*, Cheng H*. Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2. Oncogene, 2021 Sept. 23, DOI: https://doi.org/10.1038/s41388-021-02015-w.

(9) Zhang Y, Gao X, Yi J, Sang X, Dai Z, Tao Z, Wang M, Shen L, Jia Y, Xie D, Cheng H, Liu Z, Liu P*. BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell Death Dis. 2021 Jan 5;12(1):12. doi: 10.1038/s41419-020-03348-2.

(10) Sang X, Li L, Rui C, Liu Y, Liu Z, Tao Z, Cheng H*, Liu P*. Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer. Cancer Letters. 2021 Jun 18;518:82-93. doi: 10.1016/j.canlet.2021.06.011.

(11) Ding J, Yao Y, Huang G, Wang X, Yi J, Zhang N, Liu C, Wang K, Zhang Y, Wang M, Liu P*, Ye M*, Li M*, Cheng H*. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. Cancer Letters. Volume 475, 10 April 2020, Pages 53-64. doi: 10.1016/j.canlet.2020.01.032

(12) Wang M, Xue Y, Shen L, Qin P, Sang X, Tao Z, Yi J, Wang J, Liu P*, Cheng H*. Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer. Redox Biology, 2019 June, 101225. https://doi.org/10.1016/j.redox.2019.101225

(13) Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, Shen L, Xue Y, Jiang K, Luo F, Liu P*, Cheng H*. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. Ebiomedicine. 2019 Mar 18. pii: S2352-3964 (19) 30167-7. doi: 10.1016/j.ebiom.2019.03.027.

(14) Ding J, Wang X, Zhang Y, Sang X, Yi J, Liu C, Liu Z, Wang M, Zhang N, Xue Y, Shen L, Zhao W, Luo F, Liu P*, Cheng H*. Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα. Cancer Letters. 2019 Jan;440-441:54-63. doi: 10.1016/j.canlet.2018.09.030. Epub 2018 Oct 10.

(15) Usman MW, Gao J, Zheng T, Rui C, Li T, Bian X, Cheng H*, Liu P*, Luo F*. Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-kB signaling. Cell Death Dis. 2018 Jul 24;9(8):809. doi: 10.1038/s41419-018-0849-6

(16) BianX, GaoJ, LuoF, RuiC, ZhengT, WangD, WangY, RobertsTM, Liu P*, ZhaoJJ*, ChengH*.

(17) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 25 Sep, 2017(AOP); doi: 10.1038/onc.2017.326

(18) Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P*. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.Gynecologic Oncology. 2016 Sep;142(3):548-56. doi:10.1016/j.ygyno.2016.07.092.

(19) Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ*. PIK3CAH1047R-and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2015 Dec 7. doi: 10.1038/ onc.2015.377.

(20) Zhang D, Zhu L, Li C, Mu J, Fu Y, Zhu Q, Zhou Z, Liu P*, Han C*. Sialyltransferase7A, a Klf4-responsive gene, promotes cardiomyocyte apoptosis during myocardial infarction. Basic Res Cardiol. 2015 May;110(3):28.

(21) Shi L, Gao X, Li X, Jiang N, Luo F, Gu C, Chen M*, Cheng H*, Liu P*.Ellagic Acid Enhances the Efficacy ofPI3K Inhibitor GDC-0941 in Breast Cancer Cells.Current Molecular Medicine. 2015;15(5):478-86.

(22) Usman MW, Luo F, Cheng H*, Zhao JJ*, Liu P*.Chemopreventive effects of aspirin at a glance. Biochim BiophysActa, 2015, 1855(2):254-263.

(23) Chu R, Mo G, Duan Z*, Huang M, Chang J, Li X* and Liu P*. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Communication and Signaling, 2014,12:45, doi: s12964-014-0045-y.

(24) Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ. (2014) A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Research, 2014, 74(1):15-23.

(25) Liu P†, Cheng H†, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray N, Monahan J, Schlegel R, Roberts TM, Beroukhim R, Mills GB, Zhao JJ. (2011). Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms. Nature Medicine, 2011, 17(9): 1116 -1120.

(26) Sopasakis VR†, Liu P†, Suzuki R, Kondo T, Winnay J, Tran TT, Asano T, Smyth G, Sajan MP, Farese RV, Kahn CR, Zhao JJ. Specific roles of the p110alpha isoform of phosphatidyl-inositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metabolism, 2010, 11(3):220-30.

(27) Liu P, Cheng H, Roberts T, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 2009, 8(8):627-44.

(28) Jia S†, Liu Z†, Zhang S†, Liu P†, Zhang L, Lee SH, Zhang J, Signoretti S, Loda，M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature, 2008, 454(7205):776-9.